Get started
Keyword

HER2

Description: HER2 is a cell-surface receptor protein encoded by ERBB2 that regulates cell growth and is an important target in cancer diagnosis and treatment.
OpenAlex ID: keywords/her2
Triple-Negative Breast Cancer
2010 · William D. Foulkes, Ian E. Smith, et al. · New England Journal of Medicine · 4,708
X-Tile
2004 · Robert L. Camp, Marisa Dolled-Filhart, et al. · Clinical Cancer Research · 3,750
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
2013 · Lecia V. Sequist, James Chih-Hsin Yang, et al. · Journal of Clinical Oncology · 3,225
Breast cancer
2019 · Nadia Harbeck, Frédérique Penault-Llorca, et al. · Nature Reviews Disease Primers · 2,999
Epidermal growth factor-related peptides and their receptors in human malignancies
1995 · David S. Salomon, Ralf Brandt, et al. · Critical Reviews in Oncology/Hematology · 2,690
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
2004 · Torsten O. Nielsen, Forrest D. Hsu, et al. · Clinical Cancer Research · 2,663
PDF
Anticancer potential of curcumin: preclinical and clinical studies.
2003 · Bharat B Aggarwal, Anushree Kumar, et al. · PubMed · 2,560
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
2010 · Richard A Morgan, James C Yang, et al. · Molecular Therapy · 2,536
PDF
Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots
2002 · Xingyong Wu, Hongjian Liu, et al. · Nature Biotechnology · 2,506
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 · Lyndsay Harris, Herbert Fritsche, et al. · Journal of Clinical Oncology · 2,217
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
2017 · Hongchao Pan, Richard Gray, et al. · New England Journal of Medicine · 1,827
PDF
Gastric cancer
2016 · Eric Van Cutsem, Xavier Sagaert, et al. · The Lancet · 1,795
Molecular targets of dietary agents for prevention and therapy of cancer
2006 · Bharat B. Aggarwal, Shishir Shishodia · Biochemical Pharmacology · 1,756
Current treatment and recent progress in gastric cancer
2021 · Smita S. Joshi, Brian D. Badgwell · CA A Cancer Journal for Clinicians · 1,681
PDF
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
2003 · Hyun-Soo Cho, Karen Mason, et al. · Nature · 1,613
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
2008 · D Li, L Ambrogio, et al. · Oncogene · 1,435
Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications
2014 · Nida Iqbal, Nida Iqbal, et al. · Molecular Biology International · 1,384
PDF
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
2019 · J. Mazieres, A. Drilon, et al. · Annals of Oncology · 1,357
PDF
Breast Cancer Subtypes and the Risk of Local and Regional Relapse
2010 · K. David Voduc, Maggie C.U. Cheang, et al. · Journal of Clinical Oncology · 1,245
Chemoprevention of Cancer
2008 · L W Wattenberg · Springer eBooks · 1,242
The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis
2007 · M M Moasser · Oncogene · 1,220
Ki67 in breast cancer: prognostic and predictive potential
2010 · Rinat Yerushalmi, Ryan Woods, et al. · The Lancet Oncology · 1,208
Use of Chemotherapy Plus a Monoclonal Antibody Against Her2 for Metastatic Breast Cancer That Overexpresses Her2
2009 · D Ennis J. S Lamon, B Rian L Eyland, et al. · 1,199
Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype
2008 · Maggie C.U. Cheang, David Voduc, et al. · Clinical Cancer Research · 1,196
PDF
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
2016 · Yusuke Ogitani, Tetsuo Aida, et al. · Clinical Cancer Research · 1,180
Works count: 35,740
Citation count: 681,100
Year
Topic
Type